Significant investment movements have been occurring around the biotech firm
Biogen Inc. (NASDAQ: BIIB). Various organizations such as
Public Employees Retirement System of Ohio,
First County Bank CT, and
Voloridge Investment Management have been increasing their stock holdings in Biogen. Similarly,
Woodline Partners LP and
California State Teachers Retirement System also raised their positions. Meanwhile, brokerage firms' consensus rates Biogen's stocks as a
'Hold'.
Biogen has formed a strategic research collaboration and a $1 billion RNAi therapy deal with City Therapeutics. This move into RNAi Medicine is expected to expand Biogen's offerings and potential for treating CNS diseases. Investors appear to remain interested, with new investments and increased stock positions from entities like
Toronto Dominion Bank and
Quantinno Capital Management LP.Biogen's recent Q1 earnings came out
stronger than expected, with particular strength in rare disease drugs. However, there was some downward trend in the company earnings and investor returns over the past five years. The company received FDA fast track designation for its investigational Tau-Targeting Therapy BIIB080 for Alzheimer's treatment.
Biogen BIIB News Analytics from Wed, 04 Sep 2024 07:00:00 GMT to Sat, 31 May 2025 22:22:10 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 3
